It has also been suggested that silencing miRNA-517a in melanoma patient samples results in the overexpression of CDKN1C (cyclin-dependent kinase inhibitor 1C) and suppression of the c-Jun N-terminal kinase (JNK)-mediated survival and proliferation pathway, leading to increased ROS [7]. The gene discussed is CDKN1C; the disease is melanoma.